Clinical Trial Update: Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing docetaxel to an intercalated erlotinib-docetaxel regimen in relapsed EGFR wild-type, ALK-negative non-small cell lung carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Carcinoma, Non-small Cell Lung | Phase 3 | Status: TERMINATED